Conundrums in the combined use of anticoagulants and antiplatelet drugs

Circulation

Volumn 116, Issue 3, 2007, Pages 305-315

  Schneider, David J ^a   Sobel, Burton E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Anticoagulants; Hemorrhage; Platelet aggregation inhibitors; Platelets; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN III; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9 COMPLEX; CD15 ANTIGEN; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; HIRULOG; PADGEM PROTEIN; PROTEIN S; THROMBIN; THROMBOMODULIN; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG; VON WILLEBRAND FACTOR; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTERY DISEASE; ARTERY THROMBOSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLEEDING; BLEEDING TENDENCY; BLOOD CLOTTING; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; CORONARY STENT; DEEP VEIN THROMBOSIS; DRUG ELUTING STENT; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VALVE PROSTHESIS; HEART VENTRICLE THROMBOSIS; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERTENSION; IN-STENT RESTENOSIS; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; LUNG EMBOLISM; MITRAL VALVE STENOSIS; MONOTHERAPY; NEGATIVE FEEDBACK; PATIENT MONITORING; POSITIVE FEEDBACK; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN C DEFICIENCY; PROTEIN PROTEIN INTERACTION; PROTEIN S DEFICIENCY; PROTHROMBIN TIME; REVIEW; RHEUMATIC HEART DISEASE; RISK REDUCTION; SKIN NECROSIS; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; VALVULAR HEART DISEASE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 34547570583     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.655910     Document Type: Review

References (86)

1. Jesty J, Beltrami E. Positive feedbacks of coagulation. Their role in threshold regulation. Arterioscler Thromb Vasc Biol. 2005;25:2463-2469.
2. Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem. 2002;277:18322-18333.
3. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KAA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774-782.
4. Monroe DM, Hoffman M, Roberts HR. Platelets and Thrombin generation. Arterioscler Thromb Vasc Biol. 2002;22:1381-1389.
5. Krishnaswamy S, Jones KC, Mann KG. Prothrombinase complex assembly: kinetic mechanism of enzyme assembly on phospholipid vesicles. J Biol Chem. 1988;263:3823-3834.
6. Miletich JP, Jackson CM, Majerus PW. Properties of the factor Xa binding site on human platelets. J Biol Chem. 1978;253:6908-6916.
7. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood. 2000;96:170-175.
8. Tracy PB, Rohrbach MS, Mann KG. Functional prothrombinase complex assembly on isolated monocytes and lymphocytes. J Biol Chem. 1983;258:7264-7267.
9. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1:1504-1514.
10. Andrews RK, Shen Y, Gardiner EE, Berndt MC. Platelet adhesion receptors and (patho)physiological thrombus formation. Histol Histopathol. 2001;16:969-980.
11. Viskup RW, Tracy PB, Mann KG. The isolation of human platelet factor V. Blood. 1987;69:1188-1195.
12. Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood. 2000;95:1694-1702.
13. Monroe DM, Roberts HR, Hoffman M. Platelet procoagulant complex assembly in a tissue factor-initiated system. Br J Haematol. 1994;88:364-371.
14. Sixma JJ, Sakariassen KS, Stel HV, Houdijk WP, In der Maur DW, Hamer RJ, de Groot PG, van Mourik JA. Functional domains on von Willebrand factor. Recognition of discrete tryptic fragments by monoclonal antibodies that inhibit interaction of von Willebrand factor with platelets and with collagen. J Clin Invest. 1984;74:736-744.
15. Marguerie GA, Edgington TS, Plow EF. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem. 1980;255:154-160.
16. Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu YM, Sajer SA, Furie B. Leukocyte accumulation promoting fibrin deposition is mediated by P-selectin on adherent platelets. Nature. 1992;359:848-851.
17. Holmsen H, Weiss HJ. Secretable storage pools in platelets. Annu Rev Med. 1979;30:119-128.
18. Hantgan RR. A study of the kinetics of ADP-triggered platelet shape change. Blood. 1984;64:896-906.
19. Butenas S, Cawthern KM, van't Veer C, DiLorenzo ME, Lock JB, Mann KG. Antiplatelet agents in tissue factor-induced blood coagulation. Blood. 2001;97:2314-2322.
20. Rossendaal FR. Venous thrombosis: A multicausal disease. Lancet. 1999;353:1167-1173.
21. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antihrombotic therapy for venous thromboembolic disease. Chest. 2004;126:401S-428S.
22. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:338-400.
23. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:429-456.
24. Kamath S, Blann AD, Chin BS, Lip GY. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol. 2002;40:484-490.
25. ACTIVE Writing Group on behalf of the ACTIVE Investigators; Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903-12.
26. Anonymous. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 1999;83:1A-38A.
27. Loh E, Sutton MSJ, Wun CCC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moye LA, Goldhaber SZ, Pfeffer MA. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997;336:251-257.
28. Petty GW, Brown RD, Jr., Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Survival and recurrence after first cerebral infarction - A population-based study in Rochester, Minnesota 1975 through 1989. Neurology. 1998;50:208-216.
29. Vaitkus P, Barnathan ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: A meta-analysis. J Am Coll Cardiol. 1993;22:1004-1009.
30. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfaraction after myocardial infarction. N Engl J Med. 1990;323:137-152.
31. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel B, Russell RO, Smith EE, Weaver WD, Gibbons RJ, Alpert JS, Eagle KA, Gardner TJ, Garson A Jr., Gregoratos G, Smith SC Jr. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations. Circulation. 1999;100:1016-1030.
32. Pulerwitz T, Rabbani LE, Pinney SP. A rationale for the uses of anticoagulation in heart failure management. J Thromb Thrombolysis. 2004;17:87-93.
33. Spurlock BO, Chandler AB. Adherent platelets and surface microthrombi of the human aorta and left coronary artery: a scanning electron microscopy feasibility study. Scanning Microsc. 1987;1:1359-65.
34. Keating FK, Whitaker DA, Kabbani SS, Ricci MA, Sobel BE, Schneider DJ. Relation of augmented platelet reactivity to the magnitude of distribution of atherosclerosis. Am J Cardiol. 2004;94:725-728.
35. McBane RD 2nd, Karnicki K, Miller RS, Owen WG. The impact of peripheral arterial disease on circulating platelets. Thromb Res. 2004;113:137-145.
36. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, and Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003;9:61-77.
37. Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, Sarembock IJ, Ley K, Weber C. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation. 2002;106:1523-1529.
38. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets: I: acetylation of a particulate fraction protein. J Clin Invest. 1975;56:624-629.
39. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324: 71-86.
40. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, Fitzgerald D, Hirsh J, Husted S, Kvasnicka J, Montalescot G, Garcia Rodriguez LA, Verheugt F, Vermylen J, Wallentin L, Priori SG, Alonso Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Fernandez Burgos E, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Morais J Deckers J, Ferreira R, Mazzotta G, Steg PG, Teixeira F, Wilcox R; European Society of Cardiology. Expert consensus document on the use of antiplatelet agents: the task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J. 2004;25:166-181.
41. Smith SC, Jr., Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene I, Pasternak RC, Pearson T, Pfeffer MA, Starke RD, Taubert KA. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001;104:1577-1579.
42. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
43. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montale scot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717.
44. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
45. Smith SC Jr., Feldman TE, Hirshfeld JW Jr., Jacobs AK, Kern MJ, King SB III, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:e166-e286.
46. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
47. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction: Coumadin Aspirin Reinfarction Study (CARS) Investigators. Lancet. 1997;350:389-396.
48. Hurlen M, Smith P, Arnesen H. Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction: the WARIS-II (Warfarin-Aspirin Reinfarction Study) design. Scand Cardiovasc J. 2000;34:168-171.
49. Harrington RA, Becker RC, Ezekowitz M, Meade TW, O'Connor CM, Vorchheimer DA, Guyatt GH. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl 3):513S-548S.
50. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl 3):576S-599S.
51. Little SH, Massel DR. Antiplatelet and anticoagulation for patients with prosthetic heart valves. The Cochrane Library. 2006;3:1-23.
52. Chesebro JH, Fuster V, Elveback LR, McGoon DC, Pluth JR, Puga FJ, Wallace RB, Danielson GK, Orszulak TA, Piehler JM, Schaff HV. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared dipyrimadole. Am J Cardiol. 1983;51:1537-1541.
53. Bonow RO, Carabello BA, Kanu C, de Leon AC Jr., Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS, smith SC Jr., Jacobs AK, Adams CD, Anderson JL, Antman EM, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Page RL, Riegel B. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. Circulation. 2006;114:184-231.
54. Spyropoulos AC, Turpie GG. Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation. Current Opinion in Pulmonary Medicine. 2005;11:373-379.
55. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336:1506-1511.
56. Lam JY, Chesebro JH, Steele PM, Dewanjee MK, Badimon L, Fuster V. Deep arterial injury during experimental angioplasty: relation to a positive indium-111-labeled platelet scintigram, quantitative platelet deposition and mural thrombosis. J Am Coll Cardiol. 1986;8:1380-1386.
57. Bellinger DA, Nichols TC, Read MA, Reddick RL, Lamb MA, Brinkhous KM, Evatt BL, Griggs TR. Prevention of occlusive artery thrombus by a murine monoclonal antibody to porcine von Willebrand factor. Proc Natl Acad Sci U S A. 1987;84:8100-8105.
58. Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, deGuise P, Waters DD. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105-1111.
59. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 1992;327:141-145.
60. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189.
61. The Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-1497.
62. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM; ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-16.
63. Topol EJ, GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001;357:1905-1914.
64. Khurram Z, Chou E, Minutello R, Bergman G, Parikh M, Naidu S, Wong SC, Hong MK. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol. 2006;18:162-164.
65. Konstantino Y, Iakobishvili Z, Porter A, Sandach A, Zahger D, Hod H, Hammerman H, Gottlieb S, Behar S, Hasdai D. Aspirin, warfarin and a thienopyridine for acute coronary syndromes. Cardiology. 2006;105:80-85.
66. Yang X, Alexander KP, Chen AY, Roe MT, Brindis RG, Rao SV, Gibler WB, Ohman EM, Peterson ED; CRUSADE Investigators. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol. 2005;46:1490-1495.
67. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, Moliterno DJ, Lindblad L, Pieper K, Topol EJ, Stamler JS, Califf RM. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292:1555-1562.
68. Barger AP, Hurley R. Evaluation of the hypercoagulable state. Postgrad Med. 2000;108:59-66.
69. Schneider DJ. On defining aspirin resistance. J Am Coll Cardiol. 2005;46:1710-1711.
70. Cooke GE, Liu-Stratton Y, Ferketich AK, Moeschberger ML, Frid DJ, Magorien RD, Bray PF, Binklely PF, Goldschmidt-Clermont PJ. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol. 2006;47:541-546.
71. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease with influence of the 807 C/T polymorphism of the glycoprotein Ia gene. Am J Cardiol. 2005;96:1095-1099.
72. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355:809-817.
73. Schneider DJ, Tracy PB, Mann KG, and Sobel BE. Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation. 1997;96:2877-2883.
74. Rice L. Evolving management strategies for heparin-induced thrombocytopenia. Semin Hematol. 42(Suppl 3):S15-S21, 2005.
75. Bartholomew JR. Transition to an oral anticoagulant in patients with heparin-induced thrombocytopenia. Chest. 2005;127(Suppl 2):27S-34S.
76. Chan YC, Valenti D, Mansfield AO, Stansby G. Warfarin induced skin necrosis. Br J Surg. 2000;87:266-272.
77. Kam PC, Nethery CM. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia. 2003;58:28-35.
78. Savi P, Herbert JM. Clopidogrel and ticiopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005;31:174-183.
79. Undas, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol. 2005;25:287-305.
80. Krysiak R, Okopein B, Herman ZS. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs. 2003;63:1821-1854.
81. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol. 2005;46:1820-1826.
82. Alexander KP, Chen AY, Newby LK, Schwartz JB, Redberg RF, Hochman JS, Roe MT, Gibler WB, Ohman EM, Peterson ED; CRUSADE Investigators. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress. ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation. 2006;114:1380-1387.
83. Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Holoch PA, Sobel BE, Schneider DJ. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation. 2001;104:181-186.
84. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation. 1997;95:614-617.
85. Holmes MB, Schneider DJ, Hayes MG, Sobel BE, Mann KG. Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy. Circulation. 2000;102:2051-2057.
86. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682-1687.